Success Story: EB1A Approved In Just 17 Days! We Helped A Pediatric Infectious Disease Expert Secure Success with Premium Processing Service
Client’s Testimonial:
"I am deeply grateful for the exceptional expertise and seamless process provided by the team. A huge thank you for the incredible efficiency and clear guidance every step of the way."
On June 4th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Professor / Assistant Professor in the Field of Pediatric Infectious Disease (Approval Notice).
General Field: Pediatric Infectious Disease
Position at the Time of Case Filing: Professor / Assistant Professor
Country of Origin: Taiwan
Country of Residence at the Time of Filing: Taiwan
Approval Notice Date: June 4th, 2026
Processing Time: 17 days (Premium Processing Requested)
Case Summary:
We are pleased to share that the client’s I-140 EB-1A petition was approved in just 17 days after being filed directly with premium processing. The client, an established expert in pediatric infectious disease, has built a strong record of influence through research in molecular diagnostics, epidemiology, viral evolution, antimicrobial resistance, and the clinical spectrum of pediatric respiratory infections.
To demonstrate extraordinary ability, the petition presented the client’s record of 40 peer-reviewed journal articles, including 20 first-authored or co-first-authored articles, along with 4 first-authored conference abstracts. These publications were supported by 863 citations, showing that independent researchers had repeatedly relied on the client’s findings in later studies involving pediatric respiratory infections, antimicrobial resistance, RSV genomic surveillance, and evolving pathogen trends. The petition also emphasized the client’s completion of at least 18 peer reviews, which reflected recognition from journal editors and the field’s trust in the client’s ability to evaluate the work of other researchers.
A key part of the petition was explaining why these achievements mattered. We demonstrated that the client’s citation record reflected independent reliance, while the peer-review record showed sustained professional trust. We also framed the client’s original contributions around specific research areas, including pediatric intensive care infection patterns, genetic diversity and macrolide resistance in pediatric respiratory infections, and RSV surface glycoprotein variation. Together, this evidence showed that the client had developed research findings that other experts used to advance related work in infectious disease, virology, and public health preparedness.
The petition was also supported by 4 recommendation letters from experts in the field, including independent experts who recognized the client’s work through its published impact. These letters helped explain the significance of the client’s research in a way that connected the objective evidence to the broader field.
By presenting the client’s research record as a pattern of original contribution, independent reliance, and sustained peer trust, we demonstrated that the client had risen to the top of the field. We congratulate the client on this I-140 EB-1A approval and wish the client continued success in advancing pediatric infectious disease research in the United States.